Pharmacogenetics and cancer chemotherapy

European Journal of Cancer

Volumn 34, Issue 10, 1998, Pages 1493-1499

  Iyer, L ^a   Ratain, M J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Cancer; Drug metabolism; Pharmacogenetics; Polymorphism

Indexed keywords

ALDEHYDE DEHYDROGENASE; AMONAFIDE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTOCHROME P450; DIAZEPAM; DIHYDROPYRIMIDINE DEHYDROGENASE; ETOPOSIDE; FLUOROURACIL; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; HYDRALAZINE; IFOSFAMIDE; IRINOTECAN; ISONIAZID; MEPHENYTOIN; MERCAPTOPURINE; OMEPRAZOLE; PACLITAXEL; PROCAINAMIDE; PROPRANOLOL; SULFONAMIDE; TENIPOSIDE; THIOPURINE METHYLTRANSFERASE; TOLBUTAMIDE; UNINDEXED DRUG; VERAPAMIL; VINBLASTINE; VINCRISTINE; VINDESINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLON CANCER; DRUG INDUCED DISEASE; DRUG METABOLISM; ENZYME ACTIVITY; GASTROINTESTINAL SYMPTOM; GENETIC POLYMORPHISM; HUMAN; MULTIDRUG RESISTANCE; NEUROTOXICITY; NEWBORN; PHARMACOGENETICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW;

EID: 0032168144     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00230-5     Document Type: Article

References (156)

1. 1. Boddy A, Idle J. The role of pharmacogenetics in chemotherapy: modulation of tumor response and host toxicity. Cancer Sur 1993, 17, 79-104.
2. 2. Kalow W. Pharmacogenetics: its biological roots and the medical challenge. Clin Pharmacol Ther 1993, 54, 235-241.
3. 3. Dengler HJ, Eichelbaum M. Polymorphisms and deficient drug metabolism as triggers of toxic reactions. Arzneimitt Forsch 1977, 27, 1836-1844.
4. 4. Meyer UA. The molecular basis of genetic polymorphisms of drug metabolism. J Pharm Pharmacol 1994, 46, 409-415.
5. 5. Gonzalez F, Idle J. Pharmacogenetic phenotyping and genotyping: present status and future potential. Clin Pharmacokin 1994, 26, 59-70.
6. 6. Jacqz-Aigain E. Genetic polymorphisms of drug metabolism. Dev Pharmacol Ther 1989, 13, 78-84.
7. 7. Inaba T, Nebert DW, Burchell B, et al. Pharmacogenetics in clinical pharmacology and toxicology. Can J Physiol Pharmacol 1995, 73, 331-338.
8. 8. Propping P, Nothen MM. Genetic variation of CNS receptors - a new perspective for pharmacogenetics. Pharmacogenetics 1995, 5, 318-325.
9. 9. Boddy AV, Ratain MJ. Pharmacogenetics in cancer etiology and chemotherapy. Clin Cancer Res 1997, in press.
10. 10. Nebert DW, McKinnon RA, Puga A. Human drug-metabolizing enzyme polymorphisms - effects on risk of toxicity and cancer. DNA Cell Biol 1996, 15, 273-280.
11. 11. Shields P. Pharmacogenetics: detecting sensitive populations. Environ Health Perspect 1994, 102, 81-87.
12. 12. Caporaso N, Landi T, Vineis P. Relevance of metabolic polymorphisms to human carcinogenesis: evaluation of epidemioloic evidence. Pharmacogenetics 1991, 1, 4-19.
13. 13. Ikawa S, Uematsu F, Watanabe KI, et al. Assessment of cancer susceptibility in humans by use of genetic polymorphisms in carcinogen metabolism. Pharmacogenetics 1995, 5, S154-160.
14. 14. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992, 43, 329-339.
15. 15. Zimm S, Collins JM, Riccardi R, et al. Variable oral bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukaemia being optimally delivered? N Engl J Med 1983, 308, 1005-1009.
16. 16. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989, 46, 149-154.
17. 17. Krynetski EY, Tai HL, Yates CR, et al. Genetic-polymorphism of thiopurine S-methyltransferase. Clinical importance and molecular mechanisms. Pharmacogenetics 1996, 6, 279-290.
18. 18. Evans WE, Horner M, Chu YQ, Kalwinsky D, Roberts WM. Altered mercaptopurine metabolism, toxic effects and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Ped 1991, 119, 985-989.
19. 19. Lennard L, Lilleyman JS, van Loon J, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute leukaemia. Lancet 1990, 336, 225-229.
20. 20. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Gen 1980, 32, 651-652.
21. 21. McLeod HL, Lin JS, Scott EP, Pui CH, Evans WE. Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther 1994, 55, 15-20.
22. 22. Chocair PR, Duley JA, Sabbaga E, et al. Fast and slow methylators: do racial differences influence risk of allograft rejection? Q J Med 1993, 86, 359-363.
23. 23. Jang IJ, Shin SG, Lee KH, et al. Erythrocyte thiopurine methyltransferase activity in a Korean population. Br J Clin Pharmacol 1996, 42, 638-641.
24. 24. McLeod HL, Krynetski EY, Wilimas JA, Evans WE. Higher activity of polymorphic thiopurine S-methyltransferase in erythrocytes from neonates compared to adults. Pharmacogenetics 1995, 5, 281-286.
25. 25. Szumlanski C, Honchel R, Scott MC, Weinshilboum RM. Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes. Pharmacogenetics 1992, 2, 148-159.
26. 26. McLeod HL, Relling MV, Liu Q, Pui CH, Evans WE. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood 1995, 85, 1897-1902.
27. 27. Bergan S, Rugstad HE, Klemetsdal B, et al. Possibilities for therapeutic drug monitoring of azathioprine: 6-thioguanine nucleotide concentrations and thiopurine methyltransferase activity in red blood cells. Ther Drug Monit 1997, 19, 318-326.
28. 28. Lennard L, Hale HP, Lilleyman JS. Red blood cell hypoxanthine phosphoribosyltransferase activity measured using 6-mercaptopurine as a substrate: a population study in children with acute lymphoblastic leukaemia. Br J Clin Pharmacol 1993, 36, 277-284.
29. 29. Szumlanski C, Otterness D, Her C, Lee D, et al. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol 1996, 15, 17-30.
30. 30. Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997, 126, 608-614.
31. 31. Tai HL, Krynetski EY, Schuetz EG, Yanishevski Y, Evans W. Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT(Black star sign)3A, TPMT(Black star sign)2): mechanisms for the genetic polymorphism of TPMT activity. Proc Natl Acad Sci USA 1997, 94, 6444-6449.
32. 32. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokin 1989, 16, 215-237.
33. 33. Milano G, Etienne MC, Cassuto-Viguier E, et al. Influence of sex and age on fluorouracil clearance. J Clin Oncol 1992, 10, 1171-1175.
34. 34. Diasio RB, Lu Z. Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy. J Clin Oncol 1994, 12, 2239-2242.
35. 35. Morrison G, Bastian A, Rosa TD, Diasio RB, Takimoto CH. Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe averse reactions to 5-fluorouracil-based chemotherapy. Oncol Nurs Forum 1997, 24, 83-88.
36. 36. Fleming RA, Milano GA, Gaspard MH, et al. Dihydropyrimidine dehydrogenase activity in cancer patients. Eur J Cancer 1993, 29A, 740-744.
37. 37. Lu Z, Zhang R, Diasio RB. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 1993, 53, 5433-5438.
38. 38. Lu Z, Zhang R, Diasio RB. Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy. Clin Pharmacol Ther 1995, 58, 512-522.
39. 39. Tuchman M, Stoeckeler JS, Kiang DT, et al. Familial pyrimidenemia and pyrimidimuria associated with severe fluorouracil toxicity. N Engl J Med 1985, 313, 245-249.
40. 40. Diasio RB, Beavers TL, Carpenter JT. Familial deficiency of dihydropyrimidine dehydrogenase - biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 1988, 81, 47-51.
41. 41. Harris BE, Carpenter JT, Diasio RB. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase-deficiency - a potentially more common pharmacogenetic syndrome. Cancer 1991, 68, 499-501.
42. 42. Heggie GD, Sommadosi JP, Cross DS, et al. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 1987, 47, 2203-2207.
43. 43. Fernandez-Salguero P, Gonzalez FJ, Etienne MC, Milano G, Kimura S. Correlation between catalytic activity and protein content for the polymorphically expressed dihydropyrimidine dehydrogenase in human lymphocytes. Biochem Pharmacol 1995, 50, 1015-1020.
44. 44. Lyss AP, Lilenbaum RC, Harris BE, Diasio RB. Severe 5-fluorouracil toxicity in a patient with decreased dihydropyrimidine dehydrogenase activity. Cancer Invest 1993, 11, 239-240.
45. 45. Etienne MC, Lagrange JL, Dassonville O, et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 1994, 12, 2248-2253.
46. 46. McMurrough J, McLeod HL. Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population. Br J Clin Pharmacol 1996, 41, 425-427.
47. 47. Yokota H, Fernandez-Salgeuro P, Furuya H, et al. cDNA cloning and chromosome mapping of human dihydropyrimine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria. J Biol Chem 1994, 269, 23192-23196.
48. 48. Albin N, Johnson MR, Diasio RB. cDNA cloning of bovine liver dihydropyrimidine dehydrogenase. DNA Seq-J Seq Map 1996, 6, 243-250.
49. 49. Johnson MR, Wang K, Tillmanns S, Albin N, Diasio RB. Structural organization of the human dihydropyrimidine dehydrogenase gene. Cancer Res 1997, 57, 1660-1663.
50. 50. Takai S, Fernandez-Salguero P, Kimura S, Gonzalez FJ, Yamada K. Assignment of the human dihydropyrimidine dehydrogenase gene (DYPD) to chromosome region 1p22 by fluorescence in situ hybridization. Genomics 1994, 24, 613-614.
51. 51. Meinsma R, Fernandez-Salguero P, van Kulenberg AB, van Gennip AH, Gonzalez FJ. Human polymorphism in drug metabolism: mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uracilurea. DNA Cell Biol 1995, 14, 1-6.
52. 52. Vreken P, Van Kuilenburg BP, Meinsma R, et al. A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency. J Inher Metab Dis 1996, 19, 645-654.
53. 53. Ridge SA, Brown O, McMurrough J, et al. Mutations at codon 974 of the DPYD gene are a rare event. Br J Cancer 1997, 78, 178-179.
54. 54. Wei X, McLeod HL, McMurrough J, Gonzalez FJ, Fernandez-Salguero P. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest 1996, 98, 610-615.
55. 55. Fernandez-Salguero PM, Sapone A, Wei X, et al. Lack of correlation between phenotype and genotype for the polymorphically expressed dihydropyrimidine dehydrogenase in a family of Pakistani origin. Pharmacogenetics 1997, 7, 161-163.
56. 56. Tatsumi K, Yamauchi T, Kiyons K, et al. 3-cyano-2,6-dihydroxypyridine (CNDP), a new potent inhibitor of dihydrouracil dehydrogenase. J Biochem Tokyo 1993, 114, 912-918.
57. 57. Naguib FN, Hao SN, el Kouni MH. Potentiation of 5-fluorouracil efficacy by the dihydrouracil dehydrogenase inhibitor, 5-benzyloxybenzyluracil. Cancer Res 1994, 54, 5166-5170.
58. 58. Baccanari D, Davis S, Knick V, Spector T. 5-ethynyluracil (776C85) - a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil. Proc Natl Acad Sci 1993, 90, 11064-11068.
59. 59. Adjei AA, Doucett M, Spector T, et al. 5-ethynyluracil (776C85), an inhibitor of dihydropyrimidine dehydrogenase, permits reliable oral dosing of 5-fluorouracil and prolongs its half-life. Proc Am Soc Clin Oncol 1995, 14, 1478.
60. 60. Evans DAP, White TA. Human acetylation polymorphism. J Lab Clin Med 1964, 63, 394-403.
61. 61. Ohsako S, Deguchi T. Cloning and expression of cDNAs for polymorphic and monomorphic arylamine N-acetyltransferases from human liver. J Biol Chem 1990, 265, 4630-4644.
62. 62. Blum M, Grant DM, McBride W, Heim M, Meyer UA. Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol 1990, 9, 193-203.
63. 63. Vatsis KP, Weber WW. Human N-Acetyltransferases. In Kaufman FC, ed. Conjugation-Deconjugation Reactions in Drug Metabolism and Toxicity. Berlin, Springer, 1994, 109-130.
64. 64. Evans DAP. N-acetyltransferase. In Kalow W, ed. Pharmacogenetics of Drug Metabolism. New York, Pergamon Press, 1992, 95-178.
65. 65. Grant DM, Blum M, Beer M, Meyer UA. Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two genes. Mol Pharmacol 1991, 39, 184-191.
66. 66. Vatsis KP, Weber WW. Structural heterogeneity of Caucasian N-acetyltransferase at the NAT1 locus. Arch Biochem Biophys 1993, 301, 71-76.
67. 67. Okumura K, Kita T, Chikazawa S, et al. Pharmacokinetics and drug disposition-genotyping of N-acetylation polymorphism and correlation with procainamide metabolism. Clin Pharmacol Ther 1997, 61, 509-517.
68. 68. Lin HJ, Han CY, Lin BK, Hardy S. Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, Blacks, Hispanics, and Whites: application to metabolic epidemiology. Am J Hum Genet 1993, 52, 827-834.
69. 69. Lin HJ, Han CY, Lin BK, Hardy S. Ethnic distribution of slow acetylator mutations in the polymorphic N + acetyltransferase (NAT2) gene. Pharmacogenetics 1994, 4, 125-134.
70. 70. Weber WW. The Acetylator Genes and Drug Response. New York, Oxford University Press, 1987.
71. 71. Martinez C, Agundez JAG, Olivera M, Martin R, Ladero JM, Benitez J. Lung cancer and mutations at the polymorphic NAT2 gene locus. Pharmacogenetics 1995, 5, 207-214.
72. 72. Legha SS, Ring S, Raber M, et al. Phase I clinical investigation of benzisoquinolinedione. Cancer Treat Rep 1987, 71, 1165-1169.
73. 73. Leiby JM, Malspeis L, Staubuo AE, Kraut EH, Grever MR. Amonafide (NSC 308847): a clinical phase I study of two schedules of administration. Proc Am Assoc Cancer Res 1988, 29, 278.
74. 74. Ratain MJ, Mick R, Berezin F, et al. Paradoxical relationship between acetylator phenotype and amonafide toxicity. Clin Pharmacol Ther 1991, 50, 573-579.
75. 75. Ratain MJ, Mick R, Berezin F, et al. Phase I study of amonafide dosing based on acetylator phenotype. Cancer Res 1993, 53, 2304-2308.
76. 76. Ratain MJ, Rosner G, Allen S, et al. Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study. J Clin Oncol 1995, 13, 741-747.
77. 77. Ratain MJ, Mick R, Janisch L, et al. Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender. Pharmacogenetics 1996, 6, 93-101.
78. 78. Grant DM, Tang BK, Kalow W. . A simple test for acetylator phenotype using caffeine. Br J Pharmacol 1984, 17, 459-464.
79. 79. Tang DM, Kadar D, Qian L, Iriah J, Yip J, Kalow W. Caffeine as a metabolic probe: validation of its use for acetylator phenotyping. Clin Pharmacol Ther 1991, 49, 648-657.
80. 80. Hinson JA, Kadlubar FF. Glutathione and glutathione transferases in the detoxification of drug and carcinogen metabolises. In Sies H, Ketterer B, eds. Glutathione Conjugation. New York, Academic Press 1980, 235-280.
81. 81. Tsuchida S, Sato K. Glutathione transferases and cancer. CRC Crit Rev Biochem Mol 1996, 27, 337-384.
82. 82. Dirven HAAM, van Ommen B, van Bladeren PJ. Involvement of human glutathione-S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione. Cancer Res 1994, 54, 6215-6220.
83. 83. Waxman DJ. Glutathione S-transferases: role in alkylating agent resistance and possible target for modulation chemotherapy - a review. Cancer Res 1990, 50, 6449-6454.
84. 84. Lautier D, Canitrot Y, Deeley RG, Cole SPC. Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. Biochem Pharmacol 1996, 52, 967-977.
85. 85. Chen CL, Liu Q, Pui CH, et al. Higher frequency of glutathione S-transferase deletions in black children with acute lymphoblastic leukemia. Blood 1997, 89, 1701-1707.
86. 86. Board PG, Coggan M, Johnston P, et al. Genetic heterogeneity of the human glutathione transferases: a complex of gene families. Pharmacol Ther 1990, 48, 357-369.
87. 87. Inskip A, Elexperu-Camiruaga J, Buxton N, et al. Identification of polymorphism at the glutathione-S-transferase, GSTM3 locus: evidence for linkage with GSTM1(Black star sign)A. Biochem J 1995, 312, 713-716.
88. 88. Schroder KR, Wiebel FA, Reich S, Dannappel DMBH, Hallier E. Glutathione-S-transferase (GST) theta polymorphism influences background SCE rate. Arch Toxicol 1995, 69, 505-507.
89. 89. Anttila S, Luostarinen L, Hirvonen A, et al. Pulmonary expression of glutathione S-transferase M3 in lung cancer patients: association with GSTM1 polymorphism, smoking, and asbestos exposure. Cancer Res 1995, 55, 3305-3309.
90. 90. Chen C, Liu Q, Relling MV. Simultaneous characterization of glutathione S-transferase M1 and T1 polymorphisms by polymerase chain reaction in American whites and blacks. Pharmacogenetics 1996, 6, 187-191.
91. 91. Sun GF, Shimojo N, Pi JB, Lee S, Kumagai Y. Gene deficiency of glutathione s-transferase μ isoform associated with susceptibility to lung cancer in a Chinese population. Cancer Lett 1997, 113, 169-172.
92. 92. Katoh T, Nagata N, Kuroda Y, et al. Glutathione S-transferase M1 (GSTM1) and T1 (GSTT1) genetic polymorphism and susceptibility to gastric and colorectal adenocarcinoma. Carcinogenesis 1996, 17, 1855-1859.
93. 93. Yengi L, Inskip A, Gilford J, et al. Polymorphism at the glutathione S-transferase locus GSTM3: interations with cytochrome P450 and glutathione S-transferase genotypes as risk factors for multiple cutaneous basal cell carcinoma. Cancer Res 1996, 56, 1974-1977.
94. 94. Hall AG, Autzen P, Cattan AR, et al. Expression of μ class glutathione S-transferase correlates with event-free survival in childhood acute lymphoblastic leukemia. Cancer Res 1994, 54, 5251-5254.
95. 95. Dockham PA, Lee MO, Sladek NE. Identification of human liver aldehyde dehydrogenases that catalyze the oxidation of aldophosphamide and retinaldehyde. Biochem Pharmacol 1992, 43, 2453-2469.
96. 96. Nishiyori A, Fukuda K, Itoh K, Kato H. Genotype-phenotype agreement of aldehyde dehydrogenase 2 in 120 healthy Japanese. Kurume Med J 1994, 41, 117-121.
97. 97. Yoshida A. Molecular genetics of human aldehyde dehydrogenase. Pharmacogenetics 1992, 2, 139-147.
98. 98. Boddy AV, Furtun Y, Sardas S, Sardas O, Idle JR. Individual variation in the activation and inactivation metabolic pathways of cyclophosphamide. J Natl Cancer Inst 1992, 84, 1744-1748.
99. 99. Hadidi AHFA, Coulter CEA, Idle JR. Phenotypically deficient urinary elimination of carboxyphosphamide after cyclophosphamide administration to cancer patients. Cancer Res 1988, 48, 5167-5171.
100. 100. Yule SM, Boddy AV, Cole M. Cyclophosphamide metabolism in children. Cancer Res 1995, 55, 803-809.
101. 101. Boddy AV, Yule SM, Wyllie R, et al. Intrasubject variation in children of ifosfamide pharmacokinetics and metabolism during repeated administration. Cancer Chemother Pharmacol 1996, 38, 147-154.
102. 102. Burchell B, Nebert DW, Nelson DR, et al. The UDP glucuronosyltransferase gene superfamily: suggested nomenclature based on evolutionary divergence. DNA Cell Biol 1991, 10, 487-494.
103. 103. Tephly T, Green M, Pui J, Irshaid Y. Endogenous substrates for UDP-glucuronosyltransferases. Xenobiot 1988, 18, 1201-1210.
104. 104. Burchell B, Brierly CH, Rance D. Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation. Life Sci 1995, 57, 1819-1831.
105. 105. Clarke DJ, Burchell B. The uridine diphosphate glucuronosyltransferase multigene family: function and regulation. In Kaufman FC, ed. Handbook of Experimental Pharmacology. Berlin, Heidelberg, Springer, 1994, 112, 3-43.
106. 106. Parkinson A. Biotransformation of xenobiotics. In Klaassen CD, ed. Casarett and Doull's Toxicology: The Basic Science of Poisons. New York, McGraw, 1996, 113-186.
107. 107. Gupta E, Mick R, Ramirez J, et al. Pharmacokinetics and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol 1997, 15, 1502-1510.
108. 108. Gupta E, Lestingi TM, Mick R, et al. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 1994, 54, 3723-3725.
109. 109. Araki E, Ishikawa M, Ligo M, et al. Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn J Cancer Res 1993, 84, 697-702.
110. 110. Iyer L, Roy SK, Ratain MJ. In vitro glucuronidation of SN-38, the active metabolite of irinotecan (CPT-11) in human liver microsomes. Proc Am Soc Clin Oncol 1996, 15, 1589.
111. 111. Iyer L, King C, Tephly T, Ratain MJ. UGT isoform 1.1 (UGT(Black star sign)1.1) glucuronidates SN-38, the active metabolite of irinotecan. Proc Amer Soc Clin Oncol 1997, 16, 201a.
112. 112. Iyer L, Whitington P, Roy SK, Ratain MJ. Genetic basis for the glucuronidation of SN-38: role of UGT(Black star sign)1 isoform. Clin Pharmacol Ther 1997, 61, 164.
113. 113. Bosma PJ, Seppen J, Goldhoorn B, et al. Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man. J Biol Chem 1994, 269, 17960-17964.
114. 114. Crigler JF, Najjar VA. Congenital familial nonhemolytic jaundice with kernicterus. Pediatrics 1952, 10, 69-180.
115. 115. Bosma PJ, Roy Chowdhury J, Huang T-J, et al. Mechanisms of inherited deficiencies of multiple UDP-glucuronosyltransferase isoforms in two patients with Crigler-Najjar syndrome, type 1. FASEB J 1992, 2, 2859-2863.
116. 116. Gilbert A, Lereboullet P. Travaux Originaux. La Semaine Medicale 1901, 21, 241-243.
117. 117. Wasserman E, Myara A, Paumier D, et al. Baseline bilirubin (bil) and its transient early increase predicts likelihood of severe neutropenia and diarrhea in CPT-11 based chemotherapy. Proc Am Soc Oncol 1997, 16, 219a.
118. 118. Monaghan G, Ryan M, Seddon R, Hume R, Burchell B. Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 1996, 347, 578-581.
119. 119. Bosma PJ, Roy Chowdhury J, Bakker C, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995, 333, 1171-1175.
120. 120. Monaghan G, Foster B, Jurima-Romet M, Hume R, Burchell B. UGT1(Black star sign)1 genotyping in a Canadian Inuit population. Pharmacogenetics 1997, 7, 153-156.
121. 121. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977, 2, 584-586.
122. 122. Daly AK, Brockmoller J, Broly F, et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996, 6, 193-201.
123. 123. Lennard MS. Genetic polymorphism of sparteine/debrisoquine oxidation: a reappraisal. Pharmacol Toxicol 1990, 67, 273-283.
124. 124. Chen S, Chou W, Blouin R, et al. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther 1996, 60, 522-534.
125. 125. Beyeler C, Daly A, Armstrong M, et al. Phenotype/genotype relationships for the cytochrome P450 enzyme CYP2D6 in rheumatoid arthritis: influence of drug therapy and disease activity. J Rheumat 1994, 21, 1034-1039.
126. 126. Funck-Brentano C, Thomas G, Jacqz-Algrain E, et al. Polymorphism of detromethorphan metabolism: relationships between phenotype, genotype and response to the administration of encainide in humans. J Pharmacol Exp Ther 1992, 263, 780-786.
127. 127. Tseng YC, Wang SL, Lai MD, Lai ML, Huang JD. Formation of morphine from codeine in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther 1996, 60, 177-182.
128. 128. Relling MV, Evans WE, Fonne-Pfister R, Meyer UA. Anticancer drugs as inhibitors of two polymorphic cytochrome P450 enzymes, debrisoquin and mephenytoin hydroxylase, in human liver microsomes. Cancer Res 1989, 49, 68-71.
129. 129. Kupfer A, Desmond P, Patwardhan R, Schenker S, Branch RA. Mephenytoin hydroxylation deficiency: kinetics after repeated doses. Clin Pharmacol Ther 1984, 35, 33-39.
130. 130. Sullivanklose TH, Ghanayem BI, Bell DA, et al. The role of the CYP2C9-Leu(359) allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996, 6, 341-349.
131. 131. Balian JD, Sukhova N, Harris JW, et al. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism - a population study. Clin Pharmacol Ther 1995, 57, 662-669.
132. 132. Marinac JS, Balian JD, Foxworth JW, et al. Determination of CYP2C19 phenotype in black Americans with omeprazole: correlation with genotype. Clin Pharmacol Ther 1996, 60, 138-144.
133. 133. Caraco Y, Lagerstrom P-O, Wood AJJ. Ethnic and genetic determinants of omeprazole disposition and effect. Clin Pharmacol Ther 1996, 60, 157-167.
134. 134. Bertilsson L, Henthorn TK, Sanz E, et al. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin but not debrisoquine hydroxylation phenotype. Clin Pharmacol Ther 1989, 45, 348-355.
135. 135. Ward SA, Walle T, Walle UK, Wilkinson GR, Branch RA. Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther 1989, 45, 72-79.
136. 136. Goldstein JA, de Morais SMF. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994, 4, 285-299.
137. 137. Inaba T. Phenytoin: pharmacogenetic polymorphism of 4′-hydroxylation. Pharmacol Ther 1990, 46, 341-347.
138. 138. Busse D, Cosme J, Beaune P, Kroemer HK, Eichelbaum M. Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naun-Schm Arch Pharmacol 1995, 353, 116-121.
139. 139. Kleinbloesem CH, van Brummelen P, Faber H, et al. Variability in nifedipine kinetics and dynamics: a new oxidation polymorphism in man. Biochem Pharmacol 1984, 33, 3721-3724.
140. 140. Horsmans Y, Desager JP, Harvengt C. Absence of CYP3A genetic polymorphism assessed by urinary excretion of 6 beta-hydroxycortisol in 102 healthy subjects on rifampicin. Pharmacol Toxicol 1992, 71, 258-261.
141. 141. Relling MV, Evans R, Dass C, Desiderio DM, Nemec J. Human cytochrome P450 metabolism of teniposide and etoposide. J Pharmacol Exp Ther 1992, 261, 491-496.
142. 142. Chang TKH, Weber GF, Crespi CL, Waxman DJ. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 1993, 53, 5729-5737.
143. 143. Walker D, Flinois JP, Monkman SC, et al. Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochem Pharmacol 1994, 47, 1157-1163.
144. 144. Zhou XJ, Zhou-Pan XR, Gauthier T, et al. Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Biochem Pharmacol 1993, 45, 853-861.
145. 145. Wacher MJ, Chi-Yuan W, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450A and p-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinogen 1995, 13, 129-134.
146. 146. Zhou-Pan XR, Seree E, Zhou XJ, et al. Involvement of cytochrome P450 3A in vinblastine metabolism: drug interactions. Cancer Res 1993, 53, 5121-5126.
147. 147. Harris JW, Rahman A, Kim BR, Guengerich P, Collins JM. Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 1994, 54, 4026-4035.
148. 148. Royer I, Monsarrat B, Sonnier M, et al. Metabolism of docetaxel by human cytochrome P450: interactions with paclitaxel and other antineoplastic drugs. Cancer Res 1996, 56, 58-65.
149. 149. Kroemer HK, Gautier JC, Beaune P, et al. Identification of P450 enzymes involved in metabolism of verapamil in humans. Naun-Schm Arch Pharmacol 1993, 348, 332-337.
150. 150. Chabot GG. Factors involved in clinical pharmacology variability in oncology. Anticancer Res 1994, 14, 2269-2272.
151. 151. Calabrese EJ. Biochemical individuality: the next generation. Reg Toxicol Pharmacol 1996, 24, S58-S67.
152. 152. Kobayashi K, Ratain M. Individualizing dosing of cancer chemotherapy. Sem Oncol 1993, 20, 30-42.
153. 153. Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 1996, 9, 2590-2611.
154. 154. Weber JL. Human DNA polymorphisms and methods of analysis. Curr Opin Biotech 1990, 1, 166-171.
155. 155. Elrich HA, Arnheim N. Genetic analysis using the polymerase chain reaction. Ann Rev Genetics 1992, 26, 479-506.
156. 156. Vas Á. Polymerase chain reaction and other gene techniques in pharmacogenetics: an introduction and review. Acta Physiol Hung 1992, 79, 253-260.